Table 2. Univariate and multivariate competing risk analyses to identify independent risk factors for time to recurrence in patients with HCC beyond Milan criteria.
| Variable | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|
| sHR (95% CI) | P value | sHR (95% CI) | P value | ||
| Gender (female) | 0.89 (0.35–2.24) | 0.810 | NA | NA | |
| Age (>50 years) | 0.88 (0.48–1.62) | 0.690 | NA | NA | |
| HBsAg (positive) | 1.90 (0.75–4.78) | 0.170 | NA | NA | |
| AFP (>400 ng/mL) | 3.19 (1.72–5.91) | <0.001 | 2.33 (1.27–4.26) | 0.006 | |
| PIVKA-II (>100 mAU/mL) | 2.56 (1.18–5.56) | 0.018 | 1.97 (0.85–4.57) | 0.120 | |
| Child-Pugh class (B-C) | 1.36 (0.69–2.65) | 0.370 | NA | NA | |
| Cirrhosis (yes) | 0.72 (0.37–1.41) | 0.330 | NA | NA | |
| Tumor size (>5 cm) | 1.72 (0.94–3.16) | 0.078 | NA | NA | |
| Tumor number (multiple) | 0.77 (0.30–2.02) | 0.600 | NA | NA | |
| Edmondson stage (III-IV) | 2.43 (1.25–4.72) | 0.009 | 2.00 (1.00–4.00) | 0.050 | |
| mVI (yes) | 2.18 (1.05–4.53) | 0.037 | 1.20 (0.52–2.79) | 0.660 | |
| Preoperative TACE | 1.27 (0.69–2.33) | 0.450 | NA | NA | |
| Duration of surgery (minutes) | 1.00 (0.99–1.00) | 0.380 | NA | NA | |
| Blood loss (mL) | 0.97 (0.93–1.01) | 0.120 | NA | NA | |
| Warm ischemic time (minutes) | 1.00 (1.00–1.00) | 0.850 | NA | NA | |
| Lenvatinib (yes) | 0.40 (0.17–0.92) | 0.032 | 0.33 (0.13–0.83) | 0.018 | |
AFP, alpha-fetoprotein; CI, confidence interval; HBsAg, hepatitis B surface antigen; HCC, hepatocellular carcinoma; NA, not applicable; mVI, microvascular invasion; PIVKA-II, protein induced by vitamin K absence or antagonist-II; sHR, sub-hazard ratio; TACE, transarterial chemoembolization.